Objective: To evaluate the diagnostic efficacy (accuracy, sensitivity, specificity) of 1.0 M gadobutrol versus 0.5 M gadopentetate for the classification of lesions as either benign or malignant in patients with known or suspected liver lesions. Methods and Materials: A multicenter, phase-III, randomized, interindividually controlled comparison study with blinded reader evaluation was performed to investigate the diagnostic efficacy of a bolus injection of 1.0 M gadobutrol compared with 0.5 M gadopentetate at a dose of 0.1 mmol Gd/kg BW: The imaging protocol included a dynamic 3D-evaluation, static conventional, and fat saturated T1-weighted sequences. MR datasets were evaluated by 3 independent radiologists. The standard of reference was defined by an independent truth panel (radiologist or hepatologist). The safety evaluation included adverse events, vital signs, and physical examination. Results: A total of 497 of 572 patients were eligible for the final efficacy analysis. Noninferiority of gadobutrol-enhanced magnetic resonance imaging (MRI) for the classification of liver lesions was demonstrated on the basis of diagnostic accuracy determined by the on-site investigators (-0.098, 0.021) as well as for the average reader of the blinded evaluation (-0.096, 0.014) (95% confidence interval), compared with the predefined standard of reference. Very similar increases in sensitivity (ranging from similar to 10% to similar to 55%) and specificity (ranging from similar to 1%-similar to 18%) compared with precontrast MRI were also observed for the 2 contrast agent groups, with maximum differences of 4%. Very similar, low rates of adverse events were recorded for each of the 2 groups. No clinically relevant changes in vital signs or the results of the physical examination were observed in any patient. Conclusion: This study documents evidence for the noninferiority of a single i.v. bolus injection of 1.0 M gadobutrol (0.1 mmol/kg body weight) to 0.5 M gadopentetate (0.1 mmol/kg body weight) in the diagnostic assessment of liver lesions with contrast-enhanced MRI. The known excellent safety profile of gadobutrol was confirmed in this clinical trial and is similar to that of gadopentetate.

Comparison of 1.0 M Gadobutrol and 0.5 M Gadopentetate Dimeglumine-Enhanced Magnetic Resonance Imaging in Five Hundred Seventy-Two Patients With Known or Suspected Liver Lesions Results of a Multicenter, Double-Blind, Interindividual, Randomized Clinical Phase-III Trial / Renate, Hammerstingl; G., Adam; Juan Ramon, Ayuso; B. V., Beers; Giuseppe, Belfiore; Marie France, Bellin; Georg, Bongartz; Olivier, Ernst; Bernd, Frericks; Gianmarco, Giuseppetti; Gertrud Heinz, Peer; Laghi, Andrea; Julio, Martin; Christiane, Pering; Peter, Reimer; Gotz Martin, Richter; Frank W., Roemer; Fritz K. W., Schafer; Valerie, Vilgrain; Thomas J., Vogl; Dominik, Weishaupt; Alexander, Wall; Christoph J., Zech; Bernd, Tombach. - In: INVESTIGATIVE RADIOLOGY. - ISSN 0020-9996. - STAMPA. - 44:3(2009), pp. 168-176. [10.1097/rli.0b013e318198a0ae]

Comparison of 1.0 M Gadobutrol and 0.5 M Gadopentetate Dimeglumine-Enhanced Magnetic Resonance Imaging in Five Hundred Seventy-Two Patients With Known or Suspected Liver Lesions Results of a Multicenter, Double-Blind, Interindividual, Randomized Clinical Phase-III Trial

LAGHI, ANDREA;
2009

Abstract

Objective: To evaluate the diagnostic efficacy (accuracy, sensitivity, specificity) of 1.0 M gadobutrol versus 0.5 M gadopentetate for the classification of lesions as either benign or malignant in patients with known or suspected liver lesions. Methods and Materials: A multicenter, phase-III, randomized, interindividually controlled comparison study with blinded reader evaluation was performed to investigate the diagnostic efficacy of a bolus injection of 1.0 M gadobutrol compared with 0.5 M gadopentetate at a dose of 0.1 mmol Gd/kg BW: The imaging protocol included a dynamic 3D-evaluation, static conventional, and fat saturated T1-weighted sequences. MR datasets were evaluated by 3 independent radiologists. The standard of reference was defined by an independent truth panel (radiologist or hepatologist). The safety evaluation included adverse events, vital signs, and physical examination. Results: A total of 497 of 572 patients were eligible for the final efficacy analysis. Noninferiority of gadobutrol-enhanced magnetic resonance imaging (MRI) for the classification of liver lesions was demonstrated on the basis of diagnostic accuracy determined by the on-site investigators (-0.098, 0.021) as well as for the average reader of the blinded evaluation (-0.096, 0.014) (95% confidence interval), compared with the predefined standard of reference. Very similar increases in sensitivity (ranging from similar to 10% to similar to 55%) and specificity (ranging from similar to 1%-similar to 18%) compared with precontrast MRI were also observed for the 2 contrast agent groups, with maximum differences of 4%. Very similar, low rates of adverse events were recorded for each of the 2 groups. No clinically relevant changes in vital signs or the results of the physical examination were observed in any patient. Conclusion: This study documents evidence for the noninferiority of a single i.v. bolus injection of 1.0 M gadobutrol (0.1 mmol/kg body weight) to 0.5 M gadopentetate (0.1 mmol/kg body weight) in the diagnostic assessment of liver lesions with contrast-enhanced MRI. The known excellent safety profile of gadobutrol was confirmed in this clinical trial and is similar to that of gadopentetate.
2009
contrast media; diagnostic differentiation noninferiority; double-blind method; europe; female; gadobutrol; gadolinium dtpa; gadopentetate; humans; image enhancement; liver lesions; liver neoplasms; magnetic resonance imaging; male; middle aged; mri; organometallic compounds; prevalence; reproducibility of results; safety profiles; sensitivity and specificity
01 Pubblicazione su rivista::01a Articolo in rivista
Comparison of 1.0 M Gadobutrol and 0.5 M Gadopentetate Dimeglumine-Enhanced Magnetic Resonance Imaging in Five Hundred Seventy-Two Patients With Known or Suspected Liver Lesions Results of a Multicenter, Double-Blind, Interindividual, Randomized Clinical Phase-III Trial / Renate, Hammerstingl; G., Adam; Juan Ramon, Ayuso; B. V., Beers; Giuseppe, Belfiore; Marie France, Bellin; Georg, Bongartz; Olivier, Ernst; Bernd, Frericks; Gianmarco, Giuseppetti; Gertrud Heinz, Peer; Laghi, Andrea; Julio, Martin; Christiane, Pering; Peter, Reimer; Gotz Martin, Richter; Frank W., Roemer; Fritz K. W., Schafer; Valerie, Vilgrain; Thomas J., Vogl; Dominik, Weishaupt; Alexander, Wall; Christoph J., Zech; Bernd, Tombach. - In: INVESTIGATIVE RADIOLOGY. - ISSN 0020-9996. - STAMPA. - 44:3(2009), pp. 168-176. [10.1097/rli.0b013e318198a0ae]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/386737
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 34
social impact